Cancer is one of the most terrifying diagnosis that can be handed down to a patient sitting within their doctors office. Medical research is an industry unto itself and bright minds around the world are focused on finding a way to make that diagnosis just a little less intimidating. Eric Lefkofsky is one of the brighter tech minds coming out of Chicago in recent decades. He’s established himself as someone who can innovate within the specialty niche of data focused precision medicine. This specialty brought Lefkofsky to found his latest company, Tempus.
The healthcare industry is an industry that is always seemingly on the cutting edge of something new — and it’s important that it is. In order for lives to be saved, technological innovations have to be coming through the door at a record pace. A few years back the introduction of Electronic Health Records, otherwise known as EHRs, gave life to the industry. Now, years later, we know that they aren’t enough. Medical records are still notoriously sloppy and hard to corroborate between clinics and nowhere is this more apparent than within the realm of cancer-care. This is the niche that Tempus is diving into and this is the service that Lefkofsky wants to remedy.
Tempus is Eric Lefkofsky’s latest start up and his mission statement is to fundamentally change the way that cancer care and cancer research is approached. Tempus is an analytical piece of software that looks at a patient’s molecular and clinical data before streamlining the process into a digital interface. This data is primarily focused on genomic information. This data is then accessible by cancer care clinics and hospitals all around the country, at least those that interface with the Tempus system. Lefkofsky’s plan was to introduce a new operating system, sort of like a digital blanket, that lay directly over top the already implemented EHRs.
Lefkofsky is focused on the development of genome sequencing because he believes it to be the key to unlock cancer research. Lefkofsky believes, and medical research backs him up, that the human gene has the information required to find more effective paths to treatment for cancer.
To know more visit @: lefkofskyfoundation.com/about-eric-lefkofsky/